- Home
- Publications
- Publication Search
- Publication Details
Title
A Network Analysis of Multiple Myeloma Related Gene Signatures
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 10, Pages 1452
Publisher
MDPI AG
Online
2019-09-27
DOI
10.3390/cancers11101452
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular signatures of multiple myeloma progression through single cell RNA-Seq
- (2019) Jin Sung Jang et al. Blood Cancer Journal
- High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma
- (2019) Anjan Thakurta et al. BLOOD
- A Niche-Dependent Myeloid Transcriptome Signature Defines Dormant Myeloma Cells
- (2019) Weng Hua Khoo et al. BLOOD
- Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
- (2019) Benjamin G. Barwick et al. Nature Communications
- A probabilistic multi-omics data matching method for detecting sample errors in integrative analysis
- (2019) Eunjee Lee et al. GigaScience
- Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
- (2018) Brian A. Walker et al. BLOOD
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Prevalence and reporting of recruitment, randomisation and treatment errors in clinical trials: A systematic review
- (2018) Lisa N Yelland et al. Clinical Trials
- Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups
- (2018) Niccolo Bolli et al. LEUKEMIA
- Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma
- (2018) Mehmet Kemal Samur et al. LEUKEMIA
- A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
- (2018) Brian A. Walker et al. LEUKEMIA
- The multiple myelomas — current concepts in cytogenetic classification and therapy
- (2018) Shaji K. Kumar et al. Nature Reviews Clinical Oncology
- Daratumumab for the Treatment of Multiple Myeloma
- (2018) Torben Plesner et al. Frontiers in Immunology
- RNA-Seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature
- (2018) Michael A. Chapman et al. BLOOD
- Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects
- (2018) Joske Ubels et al. Nature Communications
- B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3
- (2018) Liang Lin et al. LEUKEMIA
- Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma
- (2018) Guy Ledergor et al. NATURE MEDICINE
- PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools
- (2018) Huaiyu Mi et al. NUCLEIC ACIDS RESEARCH
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
- (2017) Brian G M Durie et al. LANCET
- Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma
- (2017) A Laganà et al. LEUKEMIA
- Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
- (2017) H Goldschmidt et al. LEUKEMIA
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
- (2017) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma
- (2017) A K Mitra et al. Blood Cancer Journal
- Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials
- (2017) Manisha Bhutani et al. Lancet Haematology
- Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors
- (2017) Keiichi Ohshima et al. Scientific Reports
- Integrated Analysis of Copy Number Variations and Gene Expression Profiling in Hepatocellular carcinoma
- (2017) Chenhao Zhou et al. Scientific Reports
- Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant
- (2016) Sameh Gaballa et al. AMERICAN JOURNAL OF HEMATOLOGY
- Impact of Genes Highly Correlated withMMSETMyeloma on the Survival of Non-MMSETMyeloma Patients
- (2016) S. Peter Wu et al. CLINICAL CANCER RESEARCH
- Gene Expression Profiles in Myeloma: Ready for the Real World?
- (2016) Raphael Szalat et al. CLINICAL CANCER RESEARCH
- Treatment of relapsed and refractory multiple myeloma
- (2016) Pieter Sonneveld et al. HAEMATOLOGICA
- IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)
- (2016) J Krönke et al. LEUKEMIA
- RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response
- (2016) I J F Hofman et al. LEUKEMIA
- Genomic complexity of multiple myeloma and its clinical implications
- (2016) Salomon Manier et al. Nature Reviews Clinical Oncology
- Constructing Bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression
- (2016) Yixuan Gong et al. Oncotarget
- Treatment of relapsed and refractory multiple myeloma
- (2016) Pieter Sonneveld et al. HAEMATOLOGICA
- Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells
- (2016) Carolyne Falank et al. Frontiers in Endocrinology
- Discovery of Inhibitors for the Ether Lipid-Generating Enzyme AGPS as Anti-Cancer Agents
- (2015) Valentina Piano et al. ACS Chemical Biology
- Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System
- (2015) R. Kuiper et al. BLOOD
- Gene signature combinations improve prognostic stratification of multiple myeloma patients
- (2015) W J Chng et al. LEUKEMIA
- Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy
- (2015) T Narita et al. Blood Cancer Journal
- The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
- (2015) Carolina Terragna et al. Oncotarget
- A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy
- (2015) Alboukadel Kassambara et al. Oncotarget
- Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
- (2014) Y. X. Zhu et al. BLOOD
- Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma
- (2014) C J Heuck et al. LEUKEMIA
- MODMatcher: Multi-Omics Data Matcher for Integrative Genomic Analysis
- (2014) Seungyeul Yoo et al. PLoS Computational Biology
- Genome-Wide Screening of Cytogenetic Abnormalities in Multiple Myeloma Patients Using Array-CGH Technique: A Czech Multicenter Experience
- (2014) Jan Smetana et al. Biomed Research International
- Modeling risk stratification in human cancer
- (2013) Thierry Rème et al. BIOINFORMATICS
- Robust and tissue-independent gender-specific transcript biomarkers
- (2013) Frank Staedtler et al. BIOMARKERS
- IMWG consensus on risk stratification in multiple myeloma
- (2013) W J Chng et al. LEUKEMIA
- Classify Hyperdiploidy Status of Multiple Myeloma Patients Using Gene Expression Profiles
- (2013) Yingxiang Li et al. PLoS One
- A gene expression signature for high-risk multiple myeloma
- (2012) R Kuiper et al. LEUKEMIA
- Development of Gene Expression-Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors
- (2012) J. Moreaux et al. MOLECULAR CANCER THERAPEUTICS
- Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells
- (2012) Daniel Ramsköld et al. NATURE BIOTECHNOLOGY
- Stitching together Multiple Data Dimensions Reveals Interacting Metabolomic and Transcriptomic Networks That Modulate Cell Regulation
- (2012) Jun Zhu et al. PLOS BIOLOGY
- Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
- (2011) J. D. Shaughnessy et al. BLOOD
- Inferring causal genomic alterations in breast cancer using gene expression data
- (2011) Linh M Tran et al. BMC Systems Biology
- Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications
- (2011) Douglas W. McMillin et al. BRITISH JOURNAL OF HAEMATOLOGY
- MAGE-A Inhibits Apoptosis in Proliferating Myeloma Cells through Repression of Bax and Maintenance of Survivin
- (2011) T. Nardiello et al. CLINICAL CANCER RESEARCH
- Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide
- (2011) L. Santo et al. CLINICAL CANCER RESEARCH
- Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma
- (2011) Stefan Wilop et al. Epigenetics
- NSD2 Links Dimethylation of Histone H3 at Lysine 36 to Oncogenic Programming
- (2011) Alex J. Kuo et al. MOLECULAR CELL
- Initial genome sequencing and analysis of multiple myeloma
- (2011) Michael A. Chapman et al. NATURE
- Specimen Labeling Errors in Surgical Pathology: Table 1
- (2010) Lester J. Layfield et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
- (2010) H. Avet-Loiseau et al. BLOOD
- Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
- (2010) A. Broyl et al. BLOOD
- Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome
- (2010) N. J. Dickens et al. CLINICAL CANCER RESEARCH
- Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
- (2010) D. Hose et al. HAEMATOLOGICA
- Identification and validation of genes affecting aortic lesions in mice
- (2010) Xia Yang et al. JOURNAL OF CLINICAL INVESTIGATION
- Multiple Myeloma Bone Marrow Niche
- (2009) Grzegorz Basak et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: An integrated genomics approach reveals a wide gene dosage effect
- (2009) Luca Agnelli et al. GENES CHROMOSOMES & CANCER
- Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
- (2009) H Quach et al. LEUKEMIA
- Tumor Cell Gene Expression Changes Following Short-term In vivo Exposure to Single Agent Chemotherapeutics are Related to Survival in Multiple Myeloma
- (2008) B. Burington et al. CLINICAL CANCER RESEARCH
- Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome
- (2008) Olivier Decaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells
- (2008) Robert Evans et al. LEUKEMIA & LYMPHOMA
- Integrating large-scale functional genomic data to dissect the complexity of yeast regulatory networks
- (2008) Jun Zhu et al. NATURE GENETICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More